Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2020-08-13 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
109年第2季現金流量表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated cash flow statement for the period from January 1 to June 30, 2020 (109年第2季 in the Taiwanese calendar). It includes detailed financial data such as cash flows from operating, investing, and financing activities, with specific amounts and accounting items. The presence of actual financial statements and substantive financial data for a half-year period indicates this is a comprehensive interim financial report. The document length is 2467 characters, which is sufficient for a detailed interim report rather than a brief announcement or certification. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2020-08-13 Chinese
109年第2季綜合損益表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data including consolidated comprehensive income statements for the second quarter and half-year periods of the fiscal year 109 (Taiwan calendar year, corresponding to 2020). It includes line items such as operating income, costs, expenses, net profit/loss, and earnings per share. The presence of actual financial figures and comparative periods indicates this is a substantive financial report for a period shorter than a full fiscal year. The document length is 3623 characters, which is relatively short but contains detailed financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2020-08-13 Chinese
109年第2季資產負債表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated balance sheet with detailed financial data for multiple periods, including specific asset, liability, and equity line items. The data is presented for the second quarter of the 109th year (likely referring to a fiscal quarter) and includes comparative figures from previous periods. The presence of actual financial statements with substantive financial data indicates this is a financial report rather than an announcement or certification. The document length is 3950 characters, which is relatively short but contains detailed financial tables, suggesting it is an Interim / Quarterly Report rather than a brief announcement or a full annual report. There is no indication that this is an annual report (10-K) or a regulatory filing or announcement. Therefore, the most appropriate classification is Interim / Quarterly Report (IR).
2020-08-13 Chinese
109年第2季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial tables showing changes in equity for the first half of the fiscal year 109 (which corresponds to 2020 in the Gregorian calendar) and the previous year. It includes line items such as common stock, capital surplus, legal surplus reserve, special surplus reserve, undistributed earnings, retained earnings, and other equity components. The presence of comprehensive financial data for a half-year period indicates this is a substantive financial report rather than a brief announcement or certification. The document length is 4271 characters, which is slightly below 5000 characters, but the content is detailed financial data, not just an announcement or a certification. The document is a half-year financial report with actual financial statements and analysis, fitting the definition of an Interim / Quarterly Report (IR).
2020-08-13 Chinese
本公司經證交所同意109年8月12日恢復交易
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (1734 杏輝) stating that the stock exchange has agreed to resume trading on 109/08/12 after a suspension on 109/08/11 due to pending material information. The document is only 541 characters long and does not contain any financial data, detailed reports, or analysis. It is a regulatory announcement about trading status rather than a financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about trading resumption.
2020-08-11 Chinese
公告子公司杏國新藥股份有限公司研發中新藥SB05PC 全球胰臟癌三期人體臨床試驗期中分析(IA)分析結果。
Regulatory Filings Classification · 95% confidence The document is a short announcement (852 characters) from a listed company (杏輝) regarding the interim analysis results of a Phase III clinical trial of a new drug developed by its subsidiary. It mentions a press conference and the company's application to the stock exchange for a trading halt. There is no detailed financial data, no full report, and no indication that this is a financial report or regulatory filing beyond a general announcement. The content is about clinical trial results and related corporate actions, not fitting into financial report categories. It is a regulatory announcement about a material event affecting the company and its stock trading status. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2020-08-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.